---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-011459"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T02:11:56.407111+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Lorundrostat meets primary endpoints in Launch-HTN Phase 3 & Advance-HTN Phase 2 with significant BP reduction

## Summary
- Launch-HTN Phase 3: 50 mg lorundrostat achieved 9.1 mmHg placebo-adjusted SBP reduction (p<0.0001) at week 6 and 11.7 mmHg at week 12.
- Advance-HTN Phase 2: 50 mg achieved 7.9 mmHg placebo-adjusted SBP reduction by 24hr ABPM at week 12 (p<0.0001).
- Safety profile favorable: SAEs 2.2% (50 mg) vs 3.0% placebo; hyperkalemia (>6.0 mmol/L) 1.1% in Launch-HTN, 5.3% in Advance-HTN.
- Diverse enrollment: Launch-HTN 47% women, 29% Black/African American; Advance-HTN 40% women, 50% Black/African American.
- Full Advance-HTN results to be presented at ACC Scientific Sessions on March 29, 2025.

## SEC filing metadata
- accession: 0001628280-25-011459
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000162828025011459/0001628280-25-011459-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000162828025011459/mlys-20250310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-011459
- JSON: https://secwatch.observer/filing/0001628280-25-011459.json
- Plain text: https://secwatch.observer/filing/0001628280-25-011459.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.